Growth Metrics

Eli Lilly (LLY) Profit After Tax Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 76.51%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 133.08%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 42.47%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -51.87%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -13.81%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 26.01%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 75.17%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 712.11%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 76.51%
Dec 31, 2025 50.75%
Sep 30, 2025 56.67%
Jun 30, 2025 81.13%
Mar 31, 2025 13.18%
Dec 31, 2024 36.70%
Sep 30, 2024 -4.39%
Jun 30, 2024 28.75%
Mar 31, 2024 18.28%
Dec 31, 2023 1.13%
Sep 30, 2023 -26.98%
Jun 30, 2023 7.69%
Mar 31, 2023 -2.62%
Dec 31, 2022 9.01%
Sep 30, 2022 5.00%
Jun 30, 2022 -10.47%
Mar 31, 2022 -23.45%
Dec 31, 2021 15.46%
Sep 30, 2021 0.50%
Jun 30, 2021 100.02%
Mar 31, 2021 5.11%
Dec 31, 2020 48.54%
Sep 30, 2020 29.56%
Jun 30, 2020 11.89%
Mar 31, 2020 147.41%
Dec 31, 2019 24.68%
Sep 30, 2019 17.25%
Jun 30, 2019 21.08%
Mar 31, 2019 112.81%
Dec 31, 2018 32.84%
Sep 30, 2018 11.00%
Jun 30, 2018 -33.62%
Mar 31, 2018 30.14%
Dec 31, 2017 -80.36%
Sep 30, 2017 3.54%
Jun 30, 2017 11.18%
Mar 31, 2017 -29.11%
Dec 31, 2016 1.99%
Sep 30, 2016 -13.52%
Jun 30, 2016 -14.74%
Mar 31, 2016 -34.25%
Dec 31, 2015 -16.68%
Sep 30, 2015 -15.52%
Jun 30, 2015 -13.35%
Mar 31, 2015 -19.40%
Dec 31, 2014 -20.67%
Sep 30, 2014 -26.02%
Jun 30, 2014 -15.07%
Mar 31, 2014 -11.66%
Dec 31, 2013 -14.64%
Sep 30, 2013 -2.62%
Jun 30, 2013 -3.66%
Mar 31, 2013 7.44%
Dec 31, 2012 -3.32%
Sep 30, 2012 12.10%
Jun 30, 2012 -7.28%
Mar 31, 2012 -8.34%